MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

68.47 0.15

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

68.31

Max

68.93

Galvenie mērījumi

By Trading Economics

Ienākumi

-43M

158M

Pārdošana

-126M

1.1B

P/E

Sektora vidējais

340.5

40.527

EPS

1.16

Peļņas marža

15.025

Darbinieki

2,617

EBITDA

-80M

257M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+11.95% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.9B

13B

Iepriekšējā atvēršanas cena

68.32

Iepriekšējā slēgšanas cena

68.47

Ziņu noskaņojums

By Acuity

72%

28%

338 / 375 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūl. 23:55 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025. g. 6. jūl. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

South32 Expects to Complete Transaction in Late 2025

2025. g. 6. jūl. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

2025. g. 6. jūl. 22:34 UTC

Iegādes, apvienošanās, pārņemšana

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

2025. g. 5. jūl. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 15:57 UTC

Tirgus saruna

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Tirgus saruna

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Received All Required Authorizations

2025. g. 4. jūl. 15:48 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Agreement Was Announced on Dec. 19

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025. g. 4. jūl. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025. g. 4. jūl. 14:30 UTC

Iegādes, apvienošanās, pārņemšana

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025. g. 4. jūl. 13:53 UTC

Tirgus saruna

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. jūl. 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.95% augšup

Prognoze 12 mēnešiem

Vidējais 76.63 USD  11.95%

Augstākais 107 USD

Zemākais 52 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

7

Pirkt

9

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

338 / 375 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation